Jan 12, 2023 9:26 am EST Capricor Announces Publication Highlighting New Advances for its Engineered Exosome Platform
Nov 10, 2022 4:01 pm EST Capricor Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Nov 03, 2022 4:01 pm EDT Capricor Therapeutics to Present Third Quarter 2022 Financial Results and Recent Corporate Update on November 10
Oct 06, 2022 9:00 am EDT Capricor Therapeutics to Present One-Year Results from HOPE-2 Open Label Extension Study at World Muscle Society 2022
Aug 10, 2022 4:05 pm EDT Capricor Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Aug 03, 2022 8:00 am EDT Capricor Therapeutics to Present Second Quarter 2022 Financial Results and Recent Corporate Update on August 10
Jul 19, 2022 9:15 am EDT Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy
Jun 27, 2022 7:00 am EDT Capricor Therapeutics Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with CAP-1002 in HOPE-2 Open Label Extension Study
Jun 17, 2022 9:00 am EDT Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual Conference